التفاصيل البيبلوغرافية
| العنوان: |
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. |
| المؤلفون: |
Patel, Kishan K., Parker, Terri, Di, Mengyang, Bar, Noffar, Huntington, Scott F., Giri, Smith |
| المصدر: |
Leukemia & Lymphoma; Nov 2021, Vol. 62 Issue 11, p2777-2784, 8p |
| مصطلحات موضوعية: |
MULTIPLE myeloma, BORTEZOMIB, COST effectiveness, DEXAMETHASONE, MARKOV processes |
| مصطلحات جغرافية: |
BOSTON (Mass.) |
| مستخلص: |
The BOSTON trial showed that use of once-weekly selinexor, bortezomib, and dexamethasone (SVd) prolonged progression-free survival compared to twice-weekly bortezomib and dexamethasone (Vd) in patients with relapsed or refractory (R/R) multiple myeloma (MM). In this study, we constructed a Markov model to assess the cost-effectiveness of SVd versus Vd in R/R MM. We calculated the incremental cost-effectiveness ratio (ICER) of each treatment strategy from a US payer perspective, using a lifetime horizon and a willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY). Use of SVd was associated with an incremental cost of $170,002 compared to Vd alone ($1,015,120 vs. $845,118, respectively), an incremental effectiveness of 0.35 QALYs (3.43 vs. 3.08 QALYs, respectively), and an ICER of $487,361/QALY. These data suggest that use of once-weekly SVd for R/R M/M is unlikely to be cost-effective compared to twice-weekly Vd. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
